Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287620 · ClinicalTrials.gov registry record
Objective, Passive Assessment of LRRK2 Carriers
A clinical trial, sponsored by University of Rochester.
- Completed
- Registry status
- 10
- Enrollment target
NCT05287620: Completed study, sponsored by University of Rochester.
NCT05287620 is a clinical trial that has completed, run by University of Rochester. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287620 has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless sensor and analyzing the radio signals that bounce off patients' bodies, while patients go about their normal life without needing to wear sensors, answer questionnaires, or actively perform any tests.
Interventions
- DEVICE Emerald device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2024-05-07 |
What the finished NCT05287620 record still lists
NCT05287620 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Emerald device is the first listed.
NCT05287620 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05287620 about?
NCT05287620 is a clinical study titled "Objective, Passive Assessment of LRRK2 Carriers". The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless sensor and analyzing the radio signals that bounce off patients' bodies, while patients go about ...
What is the current status of trial NCT05287620?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2022-04-27. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT05287620?
The interventions under investigation include: Emerald device (DEVICE).
Who is sponsoring clinical trial NCT05287620?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI